Serum NGAL IN Patients With Multiple Myeloma

June 26, 2022 updated by: Ehab A. Abdelmenam, Assiut University

Serum Neutrophil Gelatinase-associated Lipocalin (NGAL) as a Predictor of Renal Injury in Patients With Multiple Myeloma

The aim of this study was to evaluate SERUM neutrophil gelatinase-associated lipocalin, emerging indicator of tubular damage and examine their relationship with established measures of renal function (serum creatinine, and estimated glomerular filtration rate, eGFR) among MM patients with and without renal impairment (RI), and at various stages of MM progression.

Study Overview

Status

Not yet recruiting

Conditions

Multiple Myeloma(MM)

Intervention / Treatment

Diagnostic test: SERUM NGAL

Detailed Description

Multiple myeloma (MM), Being one of the most common hematologic malignancies, particularly in the elderly patient, MM represents a devastating disease that occurs due to uncontrolled proliferation of a plasma cell in bone marrow , MM Presents itself with characteristic features of organ involvement: bone lesions, anemia, renal insufficiency, infections, hypercalcemia and specific malignancy biomarkers (plasma cell clonality ≥60%, involved to uninvolved serum free light chains (FLCs) ≥100 and >1 focal lesion on magnetic resonance imaging) . Additionally , Evidence of clonal plasma cell percentage of ≥10% in bone marrow or biopsy-proven plasmacytoma is necessary to define a case of MM .

MM is the second most commonly diagnosed hematological neoplasm, with an incidence rate of 5.3 per 100 000 individuals ,its incidence in Egypt 1.5 per 100 000 individuals Early mortality may not only be associated with disease progression, but also with concomitant organ involvement (i.e., renal failure) and therapy side-effects (i.e., infections) .

Production of monoclonal paraproteins, immunoglobulins (MIg) or free light chains (FLCs), is a characteristic feature of myeloma that is tied to its clinical manifestations,Although non-functional, paraproteins may be produced in excess, which alongside their physicochemical properties may precipitate the formation of lesions in vasculature and variably affect organ function. Owing to the differences between individual clones and associated MIg, kidney pathology is highly heterogeneous, with renal tubular injury associated with light chain cast nephropathy as the dominant presentation .

Renal impairment (RI) is one of the most common complications of symptomatic MM(close to one fourth of patients at the time of diagnosis). RI, defined as a serum creatinine (sCr) level > 2 mg/dL, is one of the diagnostic criteria of symptomatic MM, and it constitutes 1 of the 4 "CRAB" features (calcium level elevation, renal impairment, anemia, and bone lesions) that indicate myeloma-related organ dysfunction .. RI can carry a poor prognosis, particularly if renal function does not recover , Irreversible renal failure is less frequent, but may be present in up to 8% of patients .

The use of novel antimyeloma agents such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) as well as the improvement in supportive care has resulted in a substantial increase in patient survival. However, RI reversibility is still closely associated with MM prognosis. The persistence of severe RI is associated with significant morbidity and mortality, and remains one of the factors associated with early death, Effective anti-MM therapy and supportive care can restore renal function in several patients, Therefore, earlier recognition of disease, including its end-organ manifestations, is necessary for timely initiation and optimization of therapy but we lack biomarkers that could predict renal outcomes . Renal insufficiency is considered reversible in about 50% of cases in some reports .

Around 10% of them require haemodialysis, with a negative impact on prognosis. In addition, half of MM patients will present with at least one episode of acute kidney injury during the course of their disease. Acute kidney injury mostly reflects high tumour burden disease .

The standard assessment of renal function in patients with MM includes the measurement of sCr concentration, creatinine clearance (CrCl), blood urea nitrogen, and Estimated Glomerular Filtration Rate (eGFR), as calculated using the EPI equation. However, sCr is primarily a marker of glomerular filtration and reliant on a number of non-renal factors(comorbidity, muscle mass, medication, age), if GFR is not significantly reduced, sCr is an insensitive and late marker in the diagnosis of renal tubular injury. Novel biomarkers that will aid in predicting renal injury and chronic kidney disease development are of high interest and very early and sensitive markers .

AKI classified according to the Acute Kidney Injury Network (AKIN) classification into three stages: stage 1 Increase in serum creatinine of ≥0.3 mg/dL, stage 2 Increase in serum creatinine to 200 to 300% baseline ,stage 3 Increase in serum creatinine to >300% baseline .

One of the most promising and earliest biomarkers of kidney injury is neutrophil gelatinase-associated lipocalin (NGAL) (lipocalin 2 [LCN2]). NGAL is a lipocalin iron-carrying protein of 25 KDa expressed at low levels in several human tissues, including the kidney(16). NGAL is one of the earliest and most robust markers of acute kidney injury), reflects renal function more accurately than creatinine and correlates with both tumor burden and renal function in MM, The advantage of NGAL over conventional biomarkers of RI such as sCr and serum urea nitrogen is that the levels often increase long before any changes in sCr or urea nitrogen or urine output occur. Therefore, NGAL may also be an early, sensitive marker of RI in patients with MM .

Study Type

Observational

Enrollment (Anticipated)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Ehab ahmed Abdel moniem, assistant lecturer
Phone Number: 201097796359
Email: ehabahmed200@gmail.com

Study Contact Backup

Name: Marwa kamal abdo khairallah, assistant professor
Phone Number: 201097878113
Email: dr.marwakamal@aun.edu.eg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 71 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients will be recruited during admission and visits to Clinical Hematology Unit and outpatients clinic, Assiut university hospital, from October 2022 to October 2023.

Sample size is 60 patients diagnosed MM with or without renal impairment

Description

Inclusion Criteria:

Adult patients (>18 years) with SMM or overt multiple myeloma (MM will be confirmed based on the WHO diagnostic criteria; the presence of at least 10% plasma cells in bone marrow biopsies, presence of momoclonal protein in serum and /or urine and one of the following disorders (CRAB): hypercalcemia, renal failure, anemia, or lytic bone lesions).

Exclusion Criteria:

( other causes affect NAGAL level )
1. Patients with other plasma cell disorders (eg. Waldenstrom macroglobulinuria, MGUS, amyloidosis )
2. Recent active infection;
3. History of hepatitis B, C, or HIV
4. Neoplasms other than myeloma

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Observational Models: Cohort
Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
serum Neutrophil Gelatinase-associated Lipocalin in patients with multiple myeloma Time Frame: baseline to 3 months	Role of serum Neutrophil Gelatinase-associated Lipocalin in early detection of renal impairment in patients with multiple myeloma	baseline to 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

Study Director: Essam Abdel Monem El-beih,, professor, Assiut Univ

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

October 1, 2022

Primary Completion (Anticipated)

October 1, 2024

Study Completion (Anticipated)

January 1, 2025

Study Registration Dates

First Submitted

June 23, 2022

First Submitted That Met QC Criteria

June 26, 2022

First Posted (Actual)

June 30, 2022

Study Record Updates

Last Update Posted (Actual)